One To Watch
HUYABIO International
Company Overview
A San Diego-based biotech that licenses and globally develops novel compounds originated in China, now carrying its lead HDAC inhibitor HBI-8000 through a pivotal Phase III win in advanced melanoma. HUYABIO International's core thesis is that China's biopharma research base produces clinically credible molecules that are systematically underexploited in Western markets, and that acquiring ex-China rights early, then running rigorous multinational trials, is a faster and lower-cost route to global registration than internal discovery. With HBI-8000 already prescribed to more than 90,000 patients in approved lymphoma indications across China and Japan, the company now enters a pivotal regulatory chapter for its most commercially consequential indication yet.
Headquarters and Global Presence
HUYABIO International is headquartered in San Diego, California, with additional offices in Japan, South Korea, Canada, and Ireland, plus eight strategic locations across China. That footprint reflects the model: origination and early science sit in China, while regulatory, clinical, and commercial infrastructure spans the key ex-China markets. The HBI-8000-303 trial enrolled patients across 15 countries, which shows the company can run genuine multinational programs rather than simply repackage Chinese data.
Founding and History
HUYABIO International was founded in 2004 by Mireille Gillings and is a privately held company. The company acquired ex-China rights to tucidinostat (HBI-8000) from Shenzhen Chipscreen Biosciences in 2006, establishing what became its most advanced program. Japanese regulatory approvals for HBI-8000 in relapsed or refractory adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma followed in June and December 2021, respectively.
Therapy Areas and Focus
Oncology is HUYABIO's primary arena, with particular emphasis on hematologic malignancies and, increasingly, solid tumors including melanoma. The cardiovascular pipeline, targeting atrial fibrillation and post-myocardial infarction injury, is a parallel but earlier-stage effort. The unmet need the company is addressing in melanoma is specific: first-line patients with unresectable or metastatic disease who have not yet received a PD-1 or PD-L1 inhibitor, a population where deepening checkpoint responses through epigenetic priming remains an active clinical question.
Technology Platforms and Modalities
The company's platform is built on identifying and licensing small molecules from Chinese research institutions, then applying Western-standard clinical development to generate globally registerable data. HBI-8000 exemplifies the approach: an oral, selective class I HDAC inhibitor (targeting HDACs 1, 2, 3 and 10) that functions as an epigenetic immunomodulator. Its proposed mechanism in solid tumors is enhancement of tumor immunogenicity, making PD-1 blockade more effective. Beyond HDAC inhibition, the broader oncology portfolio reflects a deliberate push into oncogenic signaling: SHP2, KRAS G12C, MLL1-WDR5, and WEE1 are the targets, each sourced from Chinese originators and brought into HUYABIO's development engine.
Key Pipeline and Programs
HBI-8000 (tucidinostat) is the company's anchor asset, an oral class I HDAC inhibitor selective for HDACs 1, 2, 3 and 10, originally discovered by Shenzhen Chipscreen Biosciences where it is marketed as Epidaza. In its pivotal Phase III study HBI-8000-303, a randomized double-blind trial in 404 patients with unresectable or metastatic melanoma naive to PD-1/PD-L1 therapy, the combination of HBI-8000 plus nivolumab delivered median progression-free survival of 11.7 months versus 7.4 months on nivolumab plus placebo. The trial met its primary endpoint, and the company described the difference as a 58% improvement in progression-free survival. An open-label cohort within HBI-8000-303 also examined the combination in patients with brain metastases, results of which were presented as abstract 1630P in the Annals of Oncology.
HBI-2376 is a SHP2 inhibitor in Phase I development, evaluated in an open-label dose-escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations, a population chosen on SHP2's role in RAS-MAPK signaling downstream of those drivers.
HBI-2438 is a KRAS G12C inhibitor also in Phase I for solid tumors, extending the company's coverage of the oncogenic RAS pathway. Earlier-stage programs include HBI-2375, described as a first-in-class MLL1-WDR5 inhibitor in preclinical development for solid tumors and leukemia, and HBI-2448, a WEE1 inhibitor in preclinical development for solid tumors.
Recent Developments
On 14 July 2026, HUYABIO announced positive topline results from HBI-8000-303, its global Phase III trial in first-line advanced melanoma: median progression-free survival of 11.7 months with HBI-8000 plus nivolumab versus 7.4 months on nivolumab plus placebo, meeting the primary endpoint. The topline release did not include a hazard ratio, p-value, objective response rate, or overall survival data. Fuller results are expected at future medical meetings. CEO and Executive Chair Mireille Gillings characterized the outcome as a potential new standard of care addition in first-line melanoma.
Key Personnel
Mireille Gillings, PhD, Hon DSc, serves as Chief Executive Officer and Executive Chair. A Canadian-American neurobiologist and entrepreneur, she founded HUYA Bioscience International in 2004 and has led the company's strategy of globalizing China-originating biopharma assets throughout its history. Gloria Lee, MD, PhD, serves as Chief Medical Officer, overseeing clinical development across the oncology and cardiovascular portfolios. Farbod Shojaei, DVM, MSc, PhD, serves as Chief Scientific Officer, leading scientific evaluation and advancement of the pipeline, and Clement Gingras is Chief Operating Officer.
Strategic Partnerships
The most significant partnership underpinning HUYABIO's clinical strategy is its collaboration with Bristol Myers Squibb, announced on 30 March 2021, under which BMS supplies Opdivo (nivolumab) clinical drug for the HBI-8000-303 melanoma trial, with HUYABIO acting as sponsor. For commercialization in Japan and seven additional Asian markets, HUYABIO has appointed Meiji Seika Pharma as exclusive distributor for HBI-8000. The originating license for tucidinostat was acquired from Shenzhen Chipscreen Biosciences in 2006, and the ongoing relationship with Chipscreen underpins HUYABIO's access to the broader compound portfolio.
FAQ Section
HUYABIO identifies small molecules originated by Chinese research institutions, acquires ex-China development and commercial rights, then runs multinational clinical trials to global regulatory standards. The model's logic is de-risking: compounds entering HUYABIO's portfolio have typically already demonstrated early human or animal proof-of-concept in China. The Phase III melanoma win for HBI-8000 is the most consequential validation of that model to date, showing that a China-sourced asset can deliver registerable data in a competitive global oncology indication.
Histone deacetylases regulate chromatin structure and gene expression, and class I HDAC inhibition can upregulate tumor antigen presentation, increase tumor-infiltrating lymphocytes, and enhance PD-L1 expression, collectively making tumor cells more visible to immune attack. HBI-8000 selectively inhibits HDACs 1, 2, 3 and 10, and its proposed immunomodulatory effect is the mechanistic rationale for pairing it with nivolumab's PD-1 blockade. The progression-free survival result in HBI-8000-303 is the first Phase III readout for this combination, and full data have yet to be presented.
Most approved HDAC inhibitors, among them vorinostat, romidepsin and panobinostat, are broad-spectrum agents with pan-HDAC activity and significant toxicity profiles; HBI-8000's selectivity for class I HDACs (1, 2, 3) plus HDAC10 is designed to preserve immunomodulatory benefit while reducing off-target effects. Its oral bioavailability and existing real-world prescription record of more than 90,000 patients in lymphoma indications in China and Japan provide a commercial safety profile rarely available to a compound still in pivotal solid-tumor trials. The combination approach with nivolumab, rather than monotherapy, is also a deliberate positioning to differentiate from earlier-generation HDAC inhibitor failures in solid tumors.
The randomized, double-blind HBI-8000-303 trial enrolled 404 patients across 15 countries with unresectable or metastatic melanoma naive to PD-1/PD-L1 therapy, and met its primary endpoint: median progression-free survival of 11.7 months with HBI-8000 plus nivolumab versus 7.4 months with nivolumab plus placebo. The topline release did not include a hazard ratio, p-value, objective response rate or overall survival data. Those are the measures that will determine whether the reported progression-free survival benefit translates into a convincing submission package. Full data presentation at a major medical meeting remains the key near-term event.
Beyond HBI-8000's hematology and melanoma programs, HUYABIO has a cluster of oncology assets targeting oncogenic signaling: HBI-2376 (SHP2 inhibitor, Phase I in KRAS/EGFR-mutant solid tumors), HBI-2438 (KRAS G12C inhibitor, Phase I), HBI-2375 (first-in-class MLL1-WDR5 inhibitor, preclinical in solid tumors and leukemia), and HBI-2448 (WEE1 inhibitor, preclinical). A cardiovascular pipeline addresses atrial fibrillation via two multi-ion channel blockers, HBI-3000 in Phase II and HBI-3020 in Phase I/II, plus a preclinical regenerative agent for post-myocardial infarction injury, HBI-3808.
HUYABIO is a late-clinical-stage, privately held company with one approved product already generating prescription volume across multiple Asian markets (HBI-8000 in lymphoma) and now a positive Phase III readout in melanoma positioning it for regulatory submissions. The gap between the topline announcement and full data disclosure means the immediate next milestone is conference presentation and the regulatory strategy that follows. Earlier-stage programs in SHP2 and KRAS G12C inhibition are in Phase I, keeping the company's scientific relevance beyond the HBI-8000 cycle.
The pivotal watchpoints for HUYABIO center on HBI-8000-303 and the regulatory pathway that follows:
- Full data presentation at a major oncology congress, including hazard ratio, p-value and objective response rate, the metrics regulators and commercial partners need before any deal or submission can be evaluated.
- Overall survival data maturity, which will ultimately determine labeling strength and commercial positioning against established first-line melanoma regimens.
- Regulatory submission timing and agency interactions in the US, EU, and Japan, where HUYABIO already has approved indications and commercial infrastructure through Meiji Seika Pharma.
- Competitive pressure: first-line melanoma already has established checkpoint regimens, including PD-1 plus LAG-3 combinations, so HUYABIO must show a differentiated benefit-risk profile.
- Partnership or licensing deal for HBI-8000 in melanoma, which is the logical next corporate event and would validate the program's commercial value outside Asia.
Today's issue
| Headless Content Management with Blaze